Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Will Blood Clot Issues Make Johnson & Johnson's COVID Vaccine a Loser?

TheMotleyFool

0 0

Will Blood Clot Issues Make Johnson & Johnson's COVID Vaccine a Loser?

Concerns about an extremely rare blood-clotting issue have sidelined Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine for now. An advisory committee is scheduled to meet again on Friday, April 23, to review the data for reported cases of blood clots. In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli whether or not this possible side effect could make Johnson & Johnson's vaccine a loser over the longer term.

Source Fool.com

Like: 0

JNJ

Share